The FDA has asked for more information about cardiac complications reported last year in a Phase 1 study for the Molecular Templates cancer drug, MT-0169. The partial clinical hold comes as the biotech works through a corporate restructuring as well as second Nasdaq de-listing notice.
The FDA has placed a partial clinical hold on a phase 1 trial investigating MT-0169 in patients with relapsed/refractory multiple myeloma or non-Hodgkin lymphoma.
08.04.2023 - Partial hold based on previously disclosed cardiac events at 50 mcg/kg cohort; FDA to review safety data in lower dose cohortsAUSTIN, Texas, April 07, 2023 (GLOBE NEWSWIRE) - Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or . Seite 1
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.